Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific

Neuroendocrine Carcinoma

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 81/ 100

Competitive context

47 Active assets in the Neuroendocrine Carcinoma cohort.

Asset / Sponsor	Phase	Rating
Etoposide National Cancer Institute (NCI)	Phase 2	B
Everolimus AIO-Studien-gGmbH	Phase 2	B
L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R,R))- Novartis Pharmaceuticals	Phase 2	B
Lurbinectedin Jazz Pharmaceuticals	Phase 2	B
Tarlatamab National Cancer Institute (NCI)	Phase 2	B

View all 50 →

Same molecule, other indications

Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific is also rated in:

high grade malignant neoplasmActive

CCC

Indicative · Phase 2

53 / 100

View asset →

cervical carcinomaActive

CCC

Indicative · Phase 2

53 / 100

View asset →

peritoneal mesotheliomaActive

CCC